back to overview


Growth Capital Decisions – An Interview with our Co-Founder & Managing Partner Dr. Christoph Kausch

January 09, 2023 + Anja Peter
5 Min read

What do growth capital investors look for? In the following interview, our Co-Founder and Managing Partner Dr. Christoph Kausch gives insight into growth capital decisions.

Is there such a thing as the most prevalent characteristic across MTIP’s portfolio companies that convinced you to invest in them?

So overall, all of our portfolio companies are obviously within the scope of digital health, healthcare, and IT. They all originated somewhere across Europe, including Israel. What we look for are companies that really solve an important issue in the healthcare market. There are different ways how to address it, whether it’s on a medical indication or on a healthcare service area, but all of our portfolio companies work to manage accessibility, affordability, and quality of healthcare. That’s an imperative for us that the companies fulfill it. Additionally, they need to have a large impact, meaning their contribution to the market needs to be sufficiently large for us to invest in. Then, another important investment criteria is that the companies have sufficient revenue levels. We check if there’s evidence for the market to need and buy the product on a recurring basis. Once the companies have reached this kind of maturity level, they are basically in scope for us and that’s also consistent across our portfolio.

In making growth capital decisions, different investors pay more attention on different things. For some, it’s the product. For others, it’s the metrics or the team. What’s yours?

I think it’s not a single thing. Overall, it must be the combination of all the different criteria so that at the end, you have a composition of elements that you trust and believe in. You have to be sure as you can be that it’s going to be a successful investment. The first crucial element starts on a personal level. Assembling the right team becomes critical to success. Working together, sharing knowledge and ideas, and understanding everyone’s strengths and weaknesses leads to innovation, greater efficiency, and produces the best results. Clearly, the market impact, the USP from the company’s product, and the need they’re going to solve are other key criteria. After that, it trickles down to the other elements, like scalability of the business model etc. That’s where I would start.

As you are one of the first Dark Green PE funds, how do you make sure that the company you want to invest in is fully compliant with SFDR Article 9?

Well, we start already assessing the fit to our article 9 fund in our “initial assessment”. During our due diligence, we then do analyze the level of ESG/ sustainability maturity in detail and derive recommendations, what we expect the company to put in place soon after we have invested in them. Given that it is still a rather new topic, we do not yet expect the companies to be already experts in this field, but we will ensure that this will be one of the priorities going forward.

Any advice you can give to founders as they try to scale up their companies?

As a founder, you will always have to find the right balance when it comes to focusing and prioritizing on where to expand to. You will not be able to tackle everything at once. If you’re for example coming out of Switzerland and want to penetrate the other European markets as well as the American market, you shouldn’t do everything in one go. So you need to pick the battles where you want to compete because everything is resource and time intensive.

Share the Article


Diversity, Equity, and Inclusion: The 3 Key Drivers for Success

We have talked with Caroline Noublanche, CEO of our portfolio company Apricity, about her company’s DEI efforts.


Growth Capital Decisions – An Interview with our Co-Founder & Managing Partner Dr. Christoph Kausch

Growth Capital Decisions


Rahel Hafner Receives Certificate in ESG Investing by CFA Institute

Rahel Hafner Receives Certificate in ESG Investing


What Makes a Great Founder/Investor Relationship?

Interview with the CEO and Co-Founder Kai Eberhardt of our portfolio company Oviva


MTIP’s HealthCare Clinic 2022

This year's HealthCare Clinic was held under the motto: "Surfing the Healthtech Waves of Change".


Christoph Kausch selected by Real Deals as most influential for 2022

Christoph Kausch named by Real Deals most influential for 2022


MTIP leads €17 million financing round in virtual fertility clinic Apricity

New MTIP investment


MTIP leads the €20 million growth financing round in LynxCare

Largest capital round ever in digital health in Belgium


Pioneering the use of machine learning algorithms to turbo-charge drug development

Intelligencia revolutionizes drug development


The psychology of decision making

What makes a good investor?


Revolutionizing medical triage with artificial intelligence

Mediktor's solution for medical triage


MTIP Closes Second Healthtech Growth Fund Above Target With $250M of Commitments

MTIP Fund II is closed!


Cynerio Now! – A new IoT cybersecurity solution for small hospitals and clinics

Cynerio's new product Cynerio Now!


MTIP invests in Mediktor

New investment in Mediktor


SFDR Art. 8 or Art. 9? What’s the difference?

SFDR: getting the terminology right


MTIP participates in Oviva’s new $80m Series C funding

Oviva raises $80 million financing round


MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence

MTIP's new investment in Intelligencia


Private Equity 101: Part one – Glossary

Are you new to the healthtech space?


Leading brands revolutionize care journeys with Lumeon

How Lumeon orchestrates care journey


Trialbee – our hero in patient matching and recruiting for clinical trials

Trialbee - patient matching and recruiting

news blog

Digital healthcare: patient-first?

Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital

SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?

New SFDR obligations


MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation

First Closing of Fund II


How to pitch to a healthtech Investor

Blog Pitching


MTIP invests in Koa Health to make mental health treatment more accessible

New investment in Koa Health